Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse

Saad Kenderian, David L. Porter, Saar Gill

Research output: Contribution to journalReview article

35 Scopus citations

Abstract

Hematopoietic cell transplantation (HCT) remains an important and potentially curative option for most hematologic malignancies. As a form of immunotherapy, allogeneic HCT (allo-HCT) offers the potential for durable remissions but is limited by transplantation- related morbidity and mortality owing to organ toxicity, infection, and graft-versus-host disease. The recent positive outcomes of chimeric antigen receptor T (CART) cell therapy in B cell malignancies may herald a paradigm shift in the management of these disorders and perhaps other hematologic malignancies as well. Clinical trials are now needed to address the relative roles of CART cells and HCT in the context of transplantation-eligible patients. In this review, we summarize the state of the art of the development of CART cell therapy for leukemia, lymphoma, and myeloma and discuss our perspective of how CART cell therapy can be applied in the context of HCT.

Original languageEnglish (US)
Pages (from-to)235-246
Number of pages12
JournalBiology of Blood and Marrow Transplantation
Volume23
Issue number2
DOIs
StatePublished - Feb 1 2017

    Fingerprint

Keywords

  • Adoptive immunotherapy
  • Adoptive T cell therapy
  • Bone marrow transplantation
  • CART19
  • Chimeric antigen receptor T cells
  • Hematopoietic stem cell transplantation
  • Immunotherapy

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this